CN117897175A - 拓扑异构酶i抑制剂的肽缀合物的给药方案 - Google Patents
拓扑异构酶i抑制剂的肽缀合物的给药方案 Download PDFInfo
- Publication number
- CN117897175A CN117897175A CN202280044027.3A CN202280044027A CN117897175A CN 117897175 A CN117897175 A CN 117897175A CN 202280044027 A CN202280044027 A CN 202280044027A CN 117897175 A CN117897175 A CN 117897175A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- administered
- acceptable salt
- measured
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181640P | 2021-04-29 | 2021-04-29 | |
| US63/181,640 | 2021-04-29 | ||
| PCT/US2022/071967 WO2022232808A1 (en) | 2021-04-29 | 2022-04-28 | Dosing regimens of peptide conjugates of topoisomerase i inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117897175A true CN117897175A (zh) | 2024-04-16 |
Family
ID=81749580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280044027.3A Pending CN117897175A (zh) | 2021-04-29 | 2022-04-28 | 拓扑异构酶i抑制剂的肽缀合物的给药方案 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240226308A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4329817A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024516825A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240019097A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117897175A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022267389A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218253A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023003187A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308052A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012779A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202308696A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022232808A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078816A2 (en) | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| CA3032186C (en) | 2010-07-13 | 2022-04-26 | Council on Postsecondary Education, State of Rhode Island and Providence Plantations | Environmentally sensitive composition comprising a ph triggered peptide and uses thereof |
| SG10201913073YA (en) * | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| AU2019205325A1 (en) | 2018-01-05 | 2020-08-13 | Cybrexa 1, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US20210106648A1 (en) * | 2019-10-11 | 2021-04-15 | TOBEBIO Novel Drug Laboratory Co., Ltd. | Synergistic combination of chemotherapy and peptide for treating cancer |
-
2022
- 2022-04-28 JP JP2023566472A patent/JP2024516825A/ja active Pending
- 2022-04-28 CA CA3218253A patent/CA3218253A1/en active Pending
- 2022-04-28 MX MX2023012779A patent/MX2023012779A/es unknown
- 2022-04-28 AU AU2022267389A patent/AU2022267389A1/en active Pending
- 2022-04-28 EP EP22724607.1A patent/EP4329817A1/en active Pending
- 2022-04-28 TW TW111116202A patent/TW202308696A/zh unknown
- 2022-04-28 KR KR1020237040934A patent/KR20240019097A/ko active Pending
- 2022-04-28 US US18/288,650 patent/US20240226308A1/en active Pending
- 2022-04-28 CN CN202280044027.3A patent/CN117897175A/zh active Pending
- 2022-04-28 WO PCT/US2022/071967 patent/WO2022232808A1/en not_active Ceased
- 2022-04-28 IL IL308052A patent/IL308052A/en unknown
-
2023
- 2023-10-25 CL CL2023003187A patent/CL2023003187A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240019097A (ko) | 2024-02-14 |
| CA3218253A1 (en) | 2022-11-03 |
| IL308052A (en) | 2023-12-01 |
| AU2022267389A9 (en) | 2023-11-16 |
| AU2022267389A1 (en) | 2023-11-09 |
| EP4329817A1 (en) | 2024-03-06 |
| US20240226308A1 (en) | 2024-07-11 |
| MX2023012779A (es) | 2024-01-16 |
| WO2022232808A1 (en) | 2022-11-03 |
| JP2024516825A (ja) | 2024-04-17 |
| CL2023003187A1 (es) | 2024-05-03 |
| TW202308696A (zh) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110052581A1 (en) | Use of picoplatin and cetuximab to treat colorectal cancer | |
| KR20240019097A (ko) | 토포이소머라아제 i 억제제의 펩타이드 접합체 투여 요법 | |
| KR20150038297A (ko) | 아플리베르셉트 또는 지브-아플리베르셉트를 포함하는 제조 물품 | |
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| CA3018145C (en) | TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER | |
| AU2013402794A1 (en) | Cancer treatment with combination of plinabulin and taxane | |
| CN112587666A (zh) | 用于治疗癌症的pd-1/pd-l1相互作用的小分子抑制剂和抗pd-1抗体的组合 | |
| WO2020187152A1 (zh) | 治疗小细胞肺癌的联用药物组合物 | |
| KR20180021060A (ko) | 항-her2 항체-약물 접합체 및 bcl-2 억제제를 사용한 병용 요법 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2023065427A (ja) | 白金耐性癌の治療 | |
| TW202128224A (zh) | 抗pd-1抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法 | |
| JP6782932B2 (ja) | Npr−aアゴニストの新規用途 | |
| JP6359198B1 (ja) | がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤 | |
| CN107614015A (zh) | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 | |
| CN116134155A (zh) | 通过施用pd-1抑制剂治疗癌症的方法 | |
| AU2018234141A1 (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| CN114667159B (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| WO2026077321A1 (zh) | 抗her2抗体药物偶联物和免疫检查点抑制剂的药物组合 | |
| WO2023111810A1 (en) | Combination therapies and uses for treating cancer | |
| WO2023242105A9 (en) | Novel ras inhibitors | |
| CN120605325A (zh) | 靶向her2的抗原结合构建体与小分子药物联合治疗乳腺癌的用途 | |
| WO2023242102A1 (en) | Novel ras inhibitors | |
| HK1249444A1 (en) | Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer | |
| HK1155089A (en) | Use of picoplatin and bevacizumab to treat colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |